Safety and efficacy of carbon dioxide insufflation during gastric endoscopic submucosal dissection

Jun Takada, Hiroshi Araki, Fumito Onogi, Takayuki Nakanishi, Masaya Kubota, Takashi Ibuka, Masahito Shimizu, Hisataka Moriwaki

Department of Gastroenterology, Gifu University Graduate School of Medicine, Gifu 5011194, Japan

Author contributions: Takada J and Araki H contributed to the study design, acquisition and interpretation of data, and in the writing of the manuscript; Onogi F and Nakanishi T acquired the data; Kubota M and Ibuka T analyzed and interpreted the data; Shimizu M wrote the manuscript; and Moriwaki H approved the final contents of the manuscript.

Institutional review board statement: The study was reviewed and approved by the ethics committee for clinical research at Gifu University Hospital.

Clinical trial registration statement: This study is not registered.

Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

Conflict-of-interest statement: The authors declare no conflicts of interest.

Data sharing statement: The technical appendix, statistical code, and dataset are available from the corresponding author at araara@gifu-u.ac.jp. Participants gave informed consent for data sharing.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Hiroshi Araki, MD, PhD, Assistant Professor, Department of Gastroenterology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 5011194, Japan. araara@gifu-u.ac.jp Telephone: +81-58-2306308 Fax: +81-58-2306310

Received: December 12, 2014
Peer-review started: December 16, 2014
First decision: January 22, 2015
Revised: February 13, 2015
Accepted: March 18, 2015
Article in press: March 19, 2015
Published online: July 14, 2015

Abstract

AIM: To compare the safety and efficacy of carbon dioxide (CO₂) and air insufflation during gastric endoscopic submucosal dissection (ESD).

METHODS: This study involved 116 patients who underwent gastric ESD between January and December 2009. After eliminating 29 patients who fit the exclusion criteria, 87 patients, without known pulmonary dysfunction, were randomized into the CO₂ insufflation (n = 36) or air insufflation (n = 51) groups. Standard ESD was performed with a CO₂ regulation unit (constant rate of 1.4 L/min) used for patients undergoing CO₂ insufflation. Patients received diazepam for conscious sedation and pentazocine for analgesia. Transcutaneous CO₂ tension (PtcCO₂) was recorded 15 min before, during, and after ESD with insufflation. PaCO₂, the correlation between PtcCO₂ and procedure time, and ESD-related complications were compared between the two groups. Arterial blood gases were analyzed after ESD in the first 30 patients (12 with CO₂ and 18 with air insufflation) to assess the correlation between arterial blood CO₂ partial pressure (PaCO₂) and PtcCO₂.

RESULTS: There were no differences in respiratory...
functions, median sedative doses, or median procedure times between the groups. Similarly, there was no significant difference in post-ESD blood gas parameters, including PaCO$_2$, between the CO$_2$ and air groups (44.6 mmHg vs 45 mmHg). Both groups demonstrated median pH values of 7.36, and none of the patients exhibited acidemia. No significant differences were observed between the CO$_2$ and air groups with respect to baseline PtcCO$_2$ (39 mmHg vs 40 mmHg), peak PtcCO$_2$ during ESD (52 mmHg vs 51 mmHg), or median PtcCO$_2$ after ESD (50 mmHg vs 50 mmHg). There was a strong correlation between PaCO$_2$ and PtcCO$_2$ (r = 0.66; P < 0.001). The incidence of Mallory-Weiss tears was significantly lower with CO$_2$ insufflation than with air insufflation (0% vs 15.6%, P = 0.013). CO$_2$ insufflation did not cause any adverse events, such as CO$_2$ narcosis or gas embolisms.

CONCLUSION: CO$_2$ insufflation during gastric ESD results in similar blood gas levels as air insufflation, and also reduces the incidence of Mallory-Weiss tears.

Key words: Carbon dioxide; Gastric endoscopic submucosal dissection; Insufflation; Mallory-Weiss tear; Randomized controlled trial

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: The safety and efficacy of carbon dioxide (CO$_2$) and air insufflation during gastric endoscopic submucosal dissection (ESD) were compared in a randomized controlled trial. The transcutaneous CO$_2$ tension and the partial pressure of CO$_2$ in the arterial blood were measured to directly evaluate CO$_2$ retention or acidemia. The findings strongly suggest that CO$_2$ insufflation is as safe as air insufflation with regard to blood gas levels. The present study is the first randomized controlled trial to demonstrate the benefit of CO$_2$ insufflation in reducing the risk of Mallory-Weiss tears during ESD.

INTRODUCTION

Endoscopic submucosal dissection (ESD) for gastric neoplasms enables en bloc resection of even an extensive superficial lesion$^{[1-8]}$. However, gastric ESD is technically difficult and time consuming, and therefore, extensive gas insufflation is required to maintain adequate visualization during the procedure. Although air is commonly used for insufflation, it results in the retention of a large amount of residual gas after ESD. Residual gas in the gastrointestinal tract can induce post-ESD pain or discomfort, and in rare cases can give rise to life-threatening complications such as air embolism and tension pneumothorax$^{[9-17]}$.

It is well known that carbon dioxide (CO$_2$) is absorbed faster in the body than air and is also rapidly excreted through the lungs, except in cases of pulmonary dysfunction. Therefore, CO$_2$ insufflation is expected to reduce the pain and abdominal discomfort associated with endoscopic examination and therapy$^{[18-25]}$.

Perforation and major bleeding are severe complications of ESD. The reported incidence of perforation in ESD ranges from 1% to 6.1%$^{[1-5]}$, and subsequent peritonitis or mediastinitis could be fatal. CO$_2$ insufflation reportedly minimizes these ESD-related complications$^{[26]}$. The safety and efficacy of CO$_2$ insufflation during ESD for lesions of the esophagus, stomach, and colorectum have been demonstrated in randomized controlled trials (RCTs)$^{[27,28]}$ and prospective studies$^{[29-31]}$. However, these RCTs measured only transcutaneous CO$_2$ tension (PtcCO$_2$) or end-tidal CO$_2$ pressure, not partial pressure of CO$_2$ in the arterial blood (PaCO$_2$).

The aim of the present prospective RCT was to assess the safety and efficacy of CO$_2$ insufflation during ESD for gastric neoplasms in patients under conscious sedation. Both PtcCO$_2$ and PaCO$_2$ were measured in order to directly evaluate CO$_2$ retention or acidemia. Furthermore, a continuous PtcCO$_2$ measuring system to monitor patient safety during CO$_2$ insufflation was validated.

MATERIALS AND METHODS

Study design and participants

This study was designed as a single-center RCT. Between January 2009 and December 2009, all consecutive patients undergoing ESD for gastric neoplasms at Gifu University Hospital in Japan were screened for this study. Gastric ESD was indicated for differentiated adenocarcinoma that was confined to the mucosa with no risk of lymph node metastasis, and for adenoma, regardless of its size or the presence of ulceration.

Patients were excluded if: (1) they had chronic pulmonary dysfunction defined as a forced expiratory volume in 1.0 second/forced vital capacity (FEV$_1$/FVC) of < 70% or a vital capacity (%VC) of < 80%; (2) they were unable to understand the consent information required for participation; or (3) they declined participation. The study design was approved by the ethics committee for clinical research at Gifu University Hospital. All eligible individuals provided written informed consent prior to study enrollment. Randomization was conducted using sealed envelopes and patients were divided into two groups: the CO$_2$ insufflation group (CO$_2$ group) and the air insufflation group (Air group).
**Examination schedule for study events before and after ESD**

ESD was conducted during the first afternoon after hospital admission. On the second day in the hospital, blood tests, esophagogastroduodenoscopy, and CT of the chest and abdomen were performed. Blood tests for leukocyte count and C-reactive protein levels were repeated on the third hospital day. Axillary temperature was assessed 1 h after ESD and daily thereafter, at 06:00, 14:00, and 20:00 h.

**ESD procedure and conscious sedation method**

The standard ESD procedure was performed using a gastroscope with a single working channel and water jet function (GIF-Q260J; Olympus Optical Co., Tokyo, Japan) and a cap attachment (D-201-11804; Olympus). The gastric lesion was resected using either the DualKnife (KD-630L; Olympus) or the ITKnife2 (KD-611L; Olympus), depending on its location. A 0.4% high-molecular-weight hyaluronic acid solution containing epinephrine was injected into the submucosal layer to raise the lesion. Incision of the mucosal layer around the circumferential markings and subsequent direct dissection of the submucosal layer were performed with the DualKnife and ITKnife2.

Patients received diazepam for conscious sedation and pentazocine for analgesia. At the start of the ESD procedure, 5-10 mg of diazepam and 7.5-15.0 mg of pentazocine were injected intravenously for induction of anesthesia and analgesia, with an additional 5 mg of diazepam or 7.5 mg of pentazocine administered repeatedly as necessary. When the combination of diazepam and pentazocine did not achieve conscious sedation, intravenous midazolam was administered. Oxygen was administered nasally at 2.0 L/min during ESD, and the flow volume was adjusted by monitoring transcutaneous oxygen saturation (SpO2). Arterial blood samples were immediately analyzed using a blood gas analyzer (ABL700; Radiometer Medical, Copenhagen, Denmark) after the ESD procedure, for the first 30 consecutive patients.

**CO2 insufflation and transcutaneous gas analysis**

CO2 was delivered using a CO2 regulation unit (Olympus UCR; Olympus). The TOSCA measurement system and TOSCA 500 monitor (Linde Medical Sensors, Basel, Switzerland) were used to measure the PtCO2 noninvasively and continuously with an earlobe sensor attached by a low-pressure clip. We used a default temperature setting of 42°C for the sensor and recalibrated the system before each ESD. The low-flow gas tube (MAJ-1742; Olympus) of the Olympus UCR was set at a constant rate of 1.4 L/min for CO2 insufflation in all patients.

**Definitions of outcome parameters and complications**

Operation time was measured from the start of circumferential marking to the completion of resection.

---

**RESULTS**

**Patient enrollment and group allocation**

Of the 116 candidate patients for gastric ESD, 87 were enrolled in the trial and randomized. Among them, 36 received CO2 insufflation and 51 received air insufflation. Twenty-nine patients were excluded due to impaired respiratory function (n = 24), severe chronic obstructive pulmonary disease requiring oxygen (n = 3), and inability to understand the consent information required for participation (n = 2).
The first 30 participants (12 from the CO₂ group and 18 from the Air group) underwent arterial blood gas analysis (Figure 1).

**Baseline characteristics**

Baseline characteristics for each treatment group are shown in Table 1. The location of lesions and histopathology (P = 0.012) and histopathologic type (P = 0.020) of the gastric lesions were significantly different between the groups. The median procedure time was 46 min in the CO₂ group and 48 min in the Air group (not significant). There were no differences in respiratory function (FEV₁ % and %VC) between the groups. No significant differences were observed in the median dose of sedative drugs administered to the patients in each group.

**Arterial blood gas analysis**

No significant differences were observed between the two groups that received blood gas analysis after ESD with respect to the median procedure time and the median dose of sedative drugs (Table 2). There was no significant difference between the CO₂ group and the Air group in any blood gas parameters, including PaCO₂ (44.6 mmHg vs 45 mmHg). The median pH values were 7.36 in both groups, and there were no patients with acidemia. As shown in Figure 2, PtCO₂ was significantly correlated with PaCO₂ (r = 0.66; P < 0.001). The median difference between PaCO₂ and PtCO₂ was 4.8 mmHg.

**PtCO₂ and SpO₂ before and after ESD**

The median PtCO₂ before (baseline) and after ESD was 39 mmHg (28-52 mmHg) and 50 mmHg (41-68 mmHg), respectively, in the CO₂ group, and 40 mmHg (22-51 mmHg) and 50 mmHg (40-64 mmHg), respectively, in the Air group. The PtCO₂ increased significantly (P < 0.001) after the procedure in both groups, though there was no significant difference between the groups. The median peak PtCO₂ during the procedure was 52 mmHg (43-68 mmHg) in the

---

**Table 1  Patients and examination characteristics**

| Characteristic                      | CO₂ group (n = 36) | Air group (n = 51) | P value |
|-------------------------------------|--------------------|--------------------|---------|
| Age, yr                             | 74 (52-87)         | 70 (45-93)         | NS      |
| Sex, male/female                    | 22/14              | 36/15              | NS      |
| FEV₁ %                              | 72 (70-89)         | 73 (70-93)         | NS      |
| %VC                                 | 103 (80-102)       | 109 (80-152)       | NS      |
| Location of lesion, n: upper/middle/lower | 5/2/2              | 12/15/24           | 0.012   |
| Histopathologic type, n: tub1/tub2/por/sig adenoma | 18/3/0/0/15       | 36/0/2/1/6         | 0.020   |
| Histologic depth, n: M/SM1/SM2       | 32/2/2             | 42/1/18            | NS      |
| Histopathologically curative resection, n (%) | 31 (86.1)         | 43 (84.3)          | NS      |
| Tumor size, mm                      | 18 (4-75)          | 17 (3-47)          | NS      |
| Resection size, mm                  | 35 (22-110)        | 37 (23-95)         | NS      |
| Procedure time, min                 | 46 (18-194)        | 48 (15-145)        | NS      |
| Dose of diazepam, mg                | 20 (5-30)          | 20 (5-30)          | NS      |
| Dose of pentazocine, mg             | 18.8 (7.5-45)      | 22.5 (7.5-45)      | NS      |
| Patients receiving midazolam, n (%) | 3 (8.3)            | 5 (9.8)            | NS      |
| Dose of midazolam, mg               | 10.0 (2.5-20)      | 7.5 (2.5-10)       | NS      |

Data are presented as n, n (%), or median (range). FEV₁ %: Forced expiratory volume 1.0 second/forced vital capacity; %VC: Vital capacity; tub1: Well-differentiated tubular adenocarcinoma; tub2: Moderately differentiated tubular adenocarcinoma; por: Poorly differentiated adenocarcinoma; sig: Signet ring cell carcinoma; M: Tumor confined to the mucosa; SM1: Tumor confined to the submucosa and tumor invasion within 0.5 mm of the muscularis mucosae; SM2: Tumor confined to the submucosa and tumor invasion of 0.5 mm or more into the muscularis mucosae; NS: Not significant.

**Table 2  Patient characteristics and parameters of arterial blood analysis**

| Characteristic                      | CO₂ group (n = 12) | Air group (n = 18) | P value |
|-------------------------------------|--------------------|--------------------|---------|
| Age, yr                             | 73 (63-82)         | 70 (45-87)         | NS      |
| Procedure time, min                 | 66 (26-156)        | 56 (23-107)        | NS      |
| Dose of diazepam, mg                | 17.5 (10.0-22.5)   | 20.5 (5.0-30.0)    | NS      |
| Dose of pentazocine, mg             | 15.0 (15.0-30.0)   | 22.5 (15.0-37.5)   | NS      |
| Patients receiving midazolam, n (%) | 1 (8.3)            | 1 (5.6)            | NS      |
| Dose of midazolam, mg               | 2.5                | 5                  | NS      |
| pH value                            | 7.36 (7.34-7.39)   | 7.36 (7.33-7.40)   | NS      |
| PaCO₂, mmHg                         | 44.6 (39-53)       | 45 (40-50)         | NS      |
| PaO₂, mmHg                          | 168 (68-203)       | 143 (78-259)       | NS      |
| HCO₃, mmol/L                        | 25.1 (23.0-30.0)   | 25.5 (22.0-27.0)   | NS      |
| Base excess, mEq/L                  | -0.05 (-2.4)       | 0.3 (-3.1-2.6)     | NS      |

Data are presented as median (range) unless otherwise indicated. PaO₂: Partial pressure of oxygen in arterial blood; PaCO₂: Partial pressure of carbon dioxide in arterial blood; NS: Not significant.
CO₂ group and 51 mmHg (40-64 mmHg) in the Air group (not significant, Table 3). There was no correlation between the procedure time and PtcCO₂ elevation in either the CO₂ group or the Air group (Figure 3). The median minimum SpO₂ level and oxygen flow rate were similar between the groups (98% and 2.0 L/min, respectively).

Incidence of complications and duration of hospital stay

ESD-related complications and the duration of the hospital stay are listed in Table 4. CO₂ insufflation did not cause any adverse events such as CO₂ narcosis or gas embolism. No significant difference was observed between the two groups with respect to the incidence of fever (body temperature > 37.5 °C), pneumonia, perforation, or post-ESD hemorrhage. The incidence of MWTs was significantly lower in the CO₂ group than in the Air group (P = 0.013). Serum C-reactive protein levels and white blood cell counts on days 1 and 3 after ESD were not significantly different between the groups, and the median hospital stay was equivalent at 7 d for each group.

Discussion

The safety and efficacy of insufflation using CO₂ as an alternative to air has been demonstrated in several RCTs for various kinds of endoscopic procedures [18-20,22-24,27,28]. In gastric ESD, Maeda et al. [29] reported that CO₂ insufflation significantly reduced the volume of residual gas in the digestive tract compared with air insufflation. In the present study, under similar ESD conditions with regard to procedure time, respiratory function, sedative drug doses, and minimum SpO₂, neither the post-procedure PaCO₂ nor the median PtcCO₂ differed between the CO₂ group and the Air group. The peak PtcCO₂ during ESD also did not differ between the two groups. Furthermore, we confirmed a strong correlation between PaCO₂ and PtcCO₂. Therefore, the PtcCO₂ value can be used as a surrogate marker of CO₂ retention in patients who received CO₂ insufflation during ESD.

In this study, the maximum PtcCO₂ and PaCO₂ reached 68 mmHg and 53 mmHg in the CO₂ group, and 64 mmHg and 50 mmHg in the Air group, respectively. However, no adverse events such as acidemia, CO₂ narcosis, or SpO₂ depression were reported in either group. The elevated PtcCO₂ in both groups after the procedures is likely due to respiratory depression associated with conscious sedation. Several studies have demonstrated that such respiratory depression is involved in the elevation of PaCO₂ or PtcCO₂ in patients undergoing endoscopic treatment [27,29-31]. There was no correlation between procedure time and PtcCO₂ elevation in the present study. These results indicate that CO₂ insufflation is as safe as air insufflation for gastric ESD when the CO₂ insufflation rate is 1.4 L/min and the median procedure time is 48 min.

With regard to complications, the incidence of MWTs was significantly lower in the CO₂ group than in the Air group. This may be due to the rapid absorption of CO₂ by the body compared to air. Indeed, CO₂ insufflation in esophagogastroduodenoscopy efficiently reduces MWTs by lowering the tension of the gastric mucosa caused by residual gas in the stomach [32]. To our knowledge, the present study is the first RCT to demonstrate the benefit of CO₂ insufflation in reducing the risk of MWTs during ESD.

Because respiratory depression due to conscious sedation may lead to CO₂ retention, arterial CO₂ monitoring during lengthy endoscopic procedures is important, even if the patient’s respiratory function is normal. However, arterial blood sampling is invasive and it is not practical to measure PaCO₂ serially in all ESD patients. Instead, PtcCO₂, which correlates well with PaCO₂, can be measured noninvasively and continuously. PtcCO₂ is usually greater than PaCO₂ by 5-6 mmHg [33,34]. Indeed, in the present study, the median difference between these values was 4.8 mmHg. Because of the strong correlation between PtcCO₂ and PaCO₂, a PtcCO₂ monitoring system is considered a reliable and efficient alternative to PaCO₂ measuring. Thus, arterial blood analysis was not continued after the first 30 patients.

This study has some limitations. First, 27 patients (23.3%) who had chronic pulmonary dysfunction were excluded, as the safety of CO₂ insufflation during gastric ESD has not been established for these patients. We recently reported the safety of CO₂ insufflation during gastric ESD in patients with pulmonary dysfunction (FEV₁,% < 70% or %VC < 80%) under conscious sedation [35]. However, in patients with severe obstructive pulmonary disease, a longer procedure time may increase the risk of CO₂ retention because there is a significant correlation between PtcCO₂ elevation and ESD procedure time in
patients with pulmonary dysfunction. Therefore, PtcCO\(_2\) should be carefully monitored in these patients to avoid severe complications such as CO\(_2\) narcosis and acidemia. Second, the number of patients who underwent arterial blood gas analysis in the present study may be too small. The present study was also a single-center trial. Therefore, further larger prospective multicenter studies are required to confirm the safety and efficacy of CO\(_2\) insufflation for gastric ESD by evaluating both PtcCO\(_2\) and PaCO\(_2\) values.

In conclusion, this study strongly suggests that CO\(_2\) insufflation is safe and effective during gastric ESD under conscious sedation in patients without pulmonary dysfunction. Furthermore, CO\(_2\) insufflation reduces the incidence of MWTs compared to air insufflation. However, conscious sedation might increase the risk of CO\(_2\) retention and the PtcCO\(_2\) should be monitored carefully in these cases.

**COMMENTS**

**Background**

The safety and efficacy of insufflation using carbon dioxide (CO\(_2\)) as an alternative to air has been demonstrated in several randomized controlled trials for various kinds of endoscopic procedure. However, there has been no report on the safety and efficacy of CO\(_2\) insufflation for gastric endoscopic submucosal

---

### Table 3 Transcutaneous carbon dioxide tension values, transcutaneous oxygen saturation values, and oxygen flow rate

| Variable                                      | CO\(_2\) group (\(n = 36\)) | Air group (\(n = 51\)) | \(P\) value |
|-----------------------------------------------|------------------------------|-------------------------|-------------|
| Baseline PtcCO\(_2\), mmHg                    | 39 (28-52)\(^1\)            | 40 (22-51)\(^1\)       | NS          |
| PtcCO\(_2\) after ESD, mmHg                   | 50 (41-68)\(^1\)            | 50 (40-64)\(^1\)       | NS          |
| Peak PtcCO\(_2\), mmHg                        | 52 (43-68)                  | 51 (40-64)              | NS          |
| PtcCO\(_2\) > 60 mmHg during ESD              | 3 (8.3)                     | 2 (3.9)                 | NS          |
| Minimum SpO\(_2\), %                          | 98 (90-100)                 | 98 (89-100)             | NS          |
| Oxygen flow rate, L/min                       | 2 (1-5)                     | 2 (2-4)                 | NS          |

\(^1\)The PtcCO\(_2\) increased significantly (\(P < 0.001\)) after the procedure. Data are presented as \(n\) (%) or median (range). ESD: Endoscopic submucosal dissection; PtcCO\(_2\): Transcutaneous carbon dioxide tension; SpO\(_2\): Transcutaneous oxygen saturation.

---

### Table 4 Complications from endoscopic submucosal dissection, blood parameters, and duration of hospital stay

| Variable                                      | CO\(_2\) group (\(n = 36\)) | Air group (\(n = 51\)) | \(P\) value |
|-----------------------------------------------|------------------------------|-------------------------|-------------|
| Fever (body temperature > 37.5 °C)            | 9 (25.0)                    | 9 (17.6)                | NS          |
| Pneumonia                                     | 3 (8.3)                     | 5 (9.8)                 | NS          |
| Perforation                                   | 1 (2.7)                     | 1 (1.9)                 | NS          |
| Post-procedure hemorrhage                     | 0                            | 4 (7.8)                 | NS          |
| Mallory-Weiss tears                           | 0                            | 8 (9.8)                 | 0.013       |
| CRP on day 1 after ESD, mg/dL                 | 0.30 (0.09-6.19)             | 0.40 (0.04-3.62)        | NS          |
| CRP on day 3 after ESD, mg/dL                 | 2.00 (0.18-7.83)             | 2.00 (0.08-14.20)       | NS          |
| WBC on day 1 after ESD, n/µL                  | 9020 (3730-15080)            | 8090 (4310-13450)       | NS          |
| WBC on day 3 after ESD, n/µL                  | 6310 (2560-11200)            | 6260 (3105-10660)       | NS          |
| Hospital stay, d                              | 7 (7-16)                    | 7 (7-20)                | NS          |

Data are presented as \(n\) (%) or median (range). ESD: Endoscopic submucosal dissection; CRP: C-reactive protein; WBC: White blood cell.

---

![Image](image_url)
dissection (ESD) based on the measurement of both the partial pressure of CO₂ in the arterial blood and transcutaneous CO₂ tension.

**Research frontiers**

Based on the observation that CO₂ is rapidly absorbed from the bowel, this study investigated the effect of CO₂ insufflation on patients undergoing gastric ESD.

**Innovations and breakthroughs**

CO₂ insufflation remarkably reduced the incidence of Mallory-Weiss tears without any adverse events.

**Applications**

The safety and efficacy of CO₂ insufflation during gastric ESD in patients under conscious sedation were demonstrated in this study. Further investigation in patients with pulmonary dysfunction is necessary.

**Peer-review**

The present study is the first randomized controlled trial to demonstrate that CO₂ insufflation can reduce the risk of Mallory-Weiss tears during ESD, and represents a major contribution to this field.

**REFERENCES**

1. Gotoda T, Yamamoto H, Soetikno RM. Endoscopic submucosal dissection of early gastric cancer. *J Gastroenterol* 2006; 41: 929-942 [PMID: 17096062 DOI: 10.1007/s00535-006-1954-3]

2. Gotoda T. Endoscopic resection of early gastric cancer: the Japanese perspective. *Curr Opin Gastroenterology* 2006; 22: 561-569 [PMID: 16981980 DOI: 10.1097/01.mog.0000239873.06243.00]

3. Oda I, Saito D, Tada M, Iishi H, Tanabe S, Oyama T, Doi T, Otani Y, Fujisaki J, Ajyoka, Hamada T, Inoue H, Gotoda T, Yoshida S. A multicenter retrospective study of endoscopic resection for early gastric cancer. *Gastroent Endosc* 2006; 9: 262-270 [DOI: 10.1016/j.gie.2006.03.032]

4. Watanabe K, Ogata S, Kawazoe S, Watanabe K, Koyama T, Kajiwara T, Shimoda Y, Takase Y, Irie K, Mizuguchi M, Tsunada S, Iwakiri R, Fujimoto K. Advantage of endoscopic submucosal dissection and conventional mucosal resection. *Gastrointest Endosc* 2006; 64: 877-883 [PMID: 17140890 DOI: 10.1016/j.gie.2006.03.932]

5. Onozato Y, Ishihara H, Iizuka H, Sohara N, Kakizaki S, Okamura A, Moriyama Y, Ikeda T, Takeuchi H, Sato T, Oda I, Matsuda M, Kajiwara T, Shimoda Y, Takase Y, Irie K, Mizuguchi M, Tsunada S, Iwakiri R, Fujimoto K. Clinical outcomes of EMR for gastric cancers and large flat adenomas. *Endoscopy* 2006; 38: 980-986 [PMID: 17058161 DOI: 10.1055/s-2006-944809]

6. Yamamoto H, Kita H. Endoscopic therapy of early gastric tumors: histological evaluation between endoscopic submucosal dissection and conventional mucosal resection. *Gastrointest Endosc* 2006; 63: 776-782 [PMID: 1660537 DOI: 10.1016/j.gi.2005.08.049]

7. Onozato Y, Ishihara H, Iizuka H, Sohara N, Kakizaki S, Okamura A, Moriyama Y, Ikeda T, Takeuchi H, Sato T, Oda I, Matsuda M, Kajiwara T, Shimoda Y, Takase Y, Irie K, Mizuguchi M, Tsunada S, Iwakiri R, Fujimoto K. Clinical outcomes of EMR for gastric cancers and large flat adenomas. *Endoscopy* 2006; 38: 980-986 [PMID: 17058161 DOI: 10.1055/s-2006-944809]

8. Watanabe K, Ogata S, Kawazoe S, Watanabe K, Koyama T, Kajiwara T, Shimoda Y, Takase Y, Irie K, Mizuguchi M, Tsunada S, Iwakiri R, Fujimoto K. Advantage of endoscopic submucosal dissection and conventional mucosal resection. *Gastrointest Endosc* 2006; 64: 877-883 [PMID: 17140890 DOI: 10.1016/j.gie.2006.03.932]

9. Watanabe K, Ogata S, Kawazoe S, Watanabe K, Koyama T, Kajiwara T, Shimoda Y, Takase Y, Irie K, Mizuguchi M, Tsunada S, Iwakiri R, Fujimoto K. Clinical outcomes of EMR for gastric cancers and large flat adenomas. *Endoscopy* 2006; 38: 980-986 [PMID: 17058161 DOI: 10.1055/s-2006-944809]

10. Yamamoto H, Kita H. Endoscopic therapy of early gastric tumors: histological evaluation between endoscopic submucosal dissection and conventional mucosal resection. *Gastrointest Endosc* 2006; 63: 776-782 [PMID: 1660537 DOI: 10.1016/j.gi.2005.08.049]

11. Onozato Y, Ishihara H, Iizuka H, Sohara N, Kakizaki S, Okamura A, Moriyama Y, Ikeda T, Takeuchi H, Sato T, Oda I, Matsuda M, Kajiwara T, Shimoda Y, Takase Y, Irie K, Mizuguchi M, Tsunada S, Iwakiri R, Fujimoto K. Clinical outcomes of EMR for gastric cancers and large flat adenomas. *Endoscopy* 2006; 38: 980-986 [PMID: 17058161 DOI: 10.1055/s-2006-944809]

12. Watanabe K, Ogata S, Kawazoe S, Watanabe K, Koyama T, Kajiwara T, Shimoda Y, Takase Y, Irie K, Mizuguchi M, Tsunada S, Iwakiri R, Fujimoto K. Clinical outcomes of EMR for gastric cancers and large flat adenomas. *Endoscopy* 2006; 38: 980-986 [PMID: 17058161 DOI: 10.1055/s-2006-944809]

13. Watanabe K, Ogata S, Kawazoe S, Watanabe K, Koyama T, Kajiwara T, Shimoda Y, Takase Y, Irie K, Mizuguchi M, Tsunada S, Iwakiri R, Fujimoto K. Clinical outcomes of EMR for gastric cancers and large flat adenomas. *Endoscopy* 2006; 38: 980-986 [PMID: 17058161 DOI: 10.1055/s-2006-944809]
Takada J et al. CO2 insufflation for gastric ESD

28 Maeda Y, Hirasawa D, Fujita N, Ohana T, Sugawara T, Ohira T, Harada Y, Yamagata T, Suzuki K, Koike Y, Kusaka J, Tanaka M, Noda Y. A prospective, randomized, double-blind, controlled trial on the efficacy of carbon dioxide insufflation in gastric endoscopic submucosal dissection. *Endoscopy* 2013; 45: 335-341 [PMID: 23468193 DOI: 10.1055/s-0032-1326199]

29 Kikuchi T, Fu KI, Saito Y, Uraoka T, Fukuzawa M, Fukunaga S, Sakamoto T, Nakajima T, Matsuda T. Transcutaneous monitoring of partial pressure of carbon dioxide during endoscopic submucosal dissection of early colorectal neoplasia with carbon dioxide insufflation: a prospective study. *Surg Endosc* 2010; 24: 2231-2235 [PMID: 20177925 DOI: 10.1007/s00464-010-0939-8]

30 Saito Y, Uraoka T, Matsuda T, Emura F, Ikehara H, Mashimo Y, Kikuchi T, Kozu T, Saito D. A pilot study to assess the safety and efficacy of carbon dioxide insufflation during colorectal endoscopic submucosal dissection with the patient under conscious sedation. *Gastrointest Endosc* 2007; 65: 537-542 [PMID: 17321264 DOI: 10.1016/j.gie.2006.11.002]

31 Suzuki T, Minami H, Komatsu T, Masusda R, Kobayashi Y, Sakamoto A, Sato Y, Imoue H, Serada K. Prolonged carbon dioxide insufflation under general anesthesia for endoscopic submucosal dissection. *Endoscopy* 2010; 42: 1021-1029 [PMID: 21120775 DOI: 10.1055/s-0032-1255969]

32 Wang WL, Wu ZH, Sun Q, Wei JF, Chen XF, Zhou DK, Zhou L, Xie HY, Zheng SS. Meta-analysis: the use of carbon dioxide insufflation vs. room air insufflation for gastrointestinal endoscopy. *Aliment Pharmacol Ther* 2012; 35: 1145-1154 [PMID: 22452652 DOI: 10.1111/j.1365-2036.2012.05078.x]

33 Epstein MF, Cohen AR, Feldman HA, Raemer DB. Estimation of PaCO2 by two noninvasive methods in the critically ill newborn infant. *J Pediatr* 1985; 106: 282-286 [PMID: 3918157]

34 Bhavani-Shankar K, Steinbrook RA, Mushlin PS, Freiberger D. Transcutaneous PCO2 monitoring during laparoscopic cholecystectomy in pregnancy. *Can J Anaesth* 1998; 45: 164-169 [PMID: 9512853 DOI: 10.1007/BF03013257]

35 Takada J, Araki H, Onogi F, Nakanishi T, Kubota M, Ibuka T, Shimizu M, Moriwa K. Safety of carbon dioxide insufflation during gastric endoscopic submucosal dissection in patients with pulmonary dysfunction under conscious sedation. *Surg Endosc* 2015; 29: 1963-1969 [PMID: 25318364 DOI: 10.1007/s00464-014-3892-0]

P- Reviewer: Dogan UB, Lankarani KB, Sinagra E S- Editor: Ma YJ L- Editor: AmEditor E- Editor: Zhang DN
